Alpha 2.0
Login Register
» Authors » K U Kiran

K U Kiran

Explore the profile of K U Kiran including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 9
Citations 12
Followers 0
Related Specialties
Tropical Medicine
Dermatology
Infectious Diseases
Top 10 Co-Authors
J N Stanley
J M Pearson
S Suneetha
M Hogeweg
P Narasimha Rao
H M Somashekarappa
S S Rao
T D Rao
K M Eshwarappa
K Ravindraswami
Published In
Lepr Rev
Indian J Dermatol Venereol Leprol
Appl Radiat Isot
Int J Lepr Other Mycobact Dis
Affiliations
Soon will be listed here.
Recent Articles
1.
Experimental response function of a 3 in×3 in NaI(Tl) detector by inverse matrix method and effective atomic number of composite materials by gamma backscattering technique
Kiran K, Ravindraswami K, Eshwarappa K, Somashekarappa H
Appl Radiat Isot . 2016 Mar; 111:56-65. PMID: 26926377
Response function of a widely used 3in×3in NaI(Tl) detector is constructed to correct the observed pulse height distribution. A 10×10 inverse matrix is constructed using 7 mono-energetic gamma sources ((57)Co,...
2.
Relapse of leprosy presenting as nodular lymph node swelling
Kiran K, Krishna Moorthy K, Meher V, Rao P
Indian J Dermatol Venereol Leprol . 2009 Mar; 75(2):177-9. PMID: 19293508
Lymphadenopathy is known to be associated with lepromatous leprosy and has also been observed as a feature of type-2 lepra reaction. However, nodular lymph node enlargement is not commonly reported...
3.
Preventing strongyloidiasis in the immunosuppressed
Rao P, Kiran K
Indian J Dermatol Venereol Leprol . 2006 Jan; 71(5):363-4. PMID: 16394469
No abstract available.
4.
Treatment of recent facial nerve damage with lagophthalmos, using a semistandardized steroid regimen
Kiran K, Hogeweg M, Suneetha S
Lepr Rev . 1991 Jun; 62(2):150-4. PMID: 1870377
Twenty-seven patients with borderline leprosy and facial nerve damage of less than or equal to 6 months duration (36 eyes) were treated with a semistandardized regimen of steroids (the average...
5.
The significance of facial patches and type I reaction for the development of facial nerve damage in leprosy. A retrospective study among 1226 paucibacillary leprosy patients
Hogeweg M, Kiran K, Suneetha S
Lepr Rev . 1991 Jun; 62(2):143-9. PMID: 1870376
Charts of 1226 paucibacillary leprosy patients, registered between 1982 and 1987 were reviewed for recent facial nerve damage, facial patches and the presence of Type I reaction. Twenty-six (2.1%) patients...
6.
Long-term prothionamide compliance: a study carried out in India using a combined formulation containing prothionamide, dapsone and isoniazid
Ellard G, Kiran K, Stanley J
Lepr Rev . 1988 Jun; 59(2):163-75. PMID: 3246926
No abstract available.
7.
The effect of dapsone in high and normal dosage on the clinical and cell-mediated immune status of patients with borderline (BT-BL) leprosy
Rao S, Stanley J, Kiran K, Rao T, Rao P, Pearson J
Lepr Rev . 1986 Mar; 57(1):19-26. PMID: 3702577
No abstract available.
8.
The outpatient treatment of nerve damage in patients with borderline leprosy using a semi-standardized steroid regimen
Kiran K, Stanley J, Pearson J
Lepr Rev . 1985 Jun; 56(2):127-34. PMID: 4021699
No abstract available.
9.
Six cases of dapsone-resistant tuberculoid leprosy
Pearson J, Kiran K, Stanley J
Int J Lepr Other Mycobact Dis . 1984 Dec; 52(4):534-5. PMID: 6399070
No abstract available.